We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rebranding of Contrast Agent Company Creates New Markets and Growth Opportunities

By HospiMedica International staff writers
Posted on 10 Oct 2011
Agfa HealthCare (Mortsel, Belgium) announced that it is changing the name of Insight Agents, GmbH (Heidelberg, Germany) to Agfa HealthCare Imaging Agents. More...
A German company manufacturing generic contract media, Insight Agents was acquired by Agfa HealthCare in January 2010. The rebranding will support Agfa HealthCare as it extends the marketing and sales of the contrast media throughout Europe and globally.

The acquisition of Insight Agents was aimed at enhancing Agfa HealthCare’s diagnostic imaging business with a set of products that are increasingly used for diagnostic imaging procedures. The products are a logical addition to the company's successful imaging product range.

The rebranding of Insight Agents as Agfa HealthCare Imaging Agents will play a key role in extending the existing sales and marketing of the generic contrast media portfolio in Europe, as it expands its market presence globally. “Agfa HealthCare is known for in-depth knowledge of healthcare technology and clinical needs,” commented Dirk De Langhe, global business unit manager imaging agents, Agfa HealthCare. “We also have a clear goal of continuously improving our ability to deliver on-quality, on-time, and on-expectation. We will build on these strengths to maximize the growth potential of the acquisition and subsequent rebranding.”

With the increasing demand for diagnostic imaging, including in emerging markets, generic contrast media have an important role to play. “Healthcare costs are under a lot of pressure right now, but a focus on quality is still essential,” said Mr. De Langhe. “Our generic contrast media can meet both requirements.”

Agfa HealthCare Imaging Agents will continue to expand its contrast media product range as well, by developing products as existing third party patents expire. These imaging agents are not available in Canada or the United States.

Agfa HealthCare, a member of the Agfa-Gevaert Group, is a leading global provider of diagnostic imaging and healthcare information technology (IT) solutions. Agfa HealthCare develops systems for capturing, managing, and processing diagnostic images and clinical/administrative information for hospitals and healthcare facilities, as well as contrast media solutions to enable effective medical imaging results. The company has sales offices and agents in over 100 markets worldwide. Sales for Agfa HealthCare in 2010 were EUR 1.18 billion.

Related Links:
Agfa HealthCare
Insight Agents



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Vessel Sealing Instrument
ERGOseal
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.